Start typing to search

Search through charts, companies, users, and news

⬆

⬇

Navigate

ESC

↵

Open

⌘

↵

Open in new tab

Bridge Biotherapeutics Inc

#84 in public 288330.KQ public

Parataxis Korea, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide.

https://newhedge.io/api/v2/companies/bridge-biotherapeutics-inc/bitcoin-acquisitions

API Documentation

API Access Required

API access is available with our Advanced plan.

Bitcoin Holdings

Total Bitcoin ₿ 200 BTC

% of 21M Supply 0.001%

Current Value $12,337,898

Cost Basis $26,363,984

ROI -53.20%

% of Company 0.0%

mNAV

1473.69x

Market Cap $36,442,669,056

Enterprise Value $39,376,749,056

Latest Purchase Feb 06, 2026

Avg. cost / BTC $131,820

Bridge Biotherapeutics Inc Stock Priced in BTC

0.005783 BTC

Bridge Biotherapeutics Inc Bitcoin Holdings Over Time

₿ 200 BTC

Bitcoin Acquisitions History

Type	BTC Change	Holdings	Transaction Value	Date
Buy	+0 BTC	0 BTC	$0	—
Buy	+0 BTC	0 BTC	$0	—
Buy	+0 BTC	0 BTC	$0	—
Buy	+0 BTC	0 BTC	$0	—
Buy	+0 BTC	0 BTC	$0	—
Get instant access to full data Register for free

Financial Highlights

Revenue (TTM) $9,000,000

Profit Margin 0%

Operating Margin -168375.6%

ROE -90.37%

ROA -18.16%

Current Volume 0

Avg Volume (30d) 1,126,485

Volume vs Avg 0.0x

Bridge Biotherapeutics Inc Stock Price vs Bitcoin

$416.00 / $61,689

Company Overview

Parataxis Korea, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for the treatment of various fibrotic diseases, such as idiopathic pulmonary fibrosis. Bridge Biotherapeutics, Inc. has a research collaboration with Atomwise to launch small molecule programs across various therapeutic areas using structure-based AI technology for drug discovery; the University of Colorado School of Medicine to explore the potential of BBT-877 for immuno-oncology; and the Emory University School of Medicine to explore combination therapy of BBT-877 for KRAS/P53 mutant NSCLC patients resistant to anti-PD-1 blockade. The company was formerly known as Bridge Biotherapeutics, Inc. and changed its name to Parataxis Korea, Inc. in August 2025. The company was founded in 2015 and is headquartered in Seongnam-si, South Korea.

Sector Financial Services

Industry Capital Markets

Sub-Industry Coal & Consumable Fuels

Employees 21

Exchange KQ

Fiscal Year End December

Website Visit Website

Stock Returns

Share Price $416.00

1W Return -3.93%

1M Return -44.16%

3M Return -53.31%

1Y Return -93.16%

1Y vs BTC -47.2%

52W High $9280.00

% Down from 52W High -95.5%

Key Executives

Mr. Jun-Ho Kim CEO & Director

Age: 35

Mr. Jeong-Gyu Lee Inside Director & Head of Bio Business Division

Age: 58

Mr. Jong-Jin Lim Ph.D. VP & Head of Corporate Strategy

Age: 2026

Mr. Yong-Hee Lee Ph.D. Senior VP of Clinical Development & Head of Development

Age: 50

Company Details

Address C?s Tower, Seongnam-si, South Korea, 13486

Phone 82 31 8092 3282

Currency KRW

Most Recent Quarter 2025-12-31

Growth Metrics

Earnings Growth (YoY) 0%

Revenue Growth (YoY) -100%

Balance Sheet (Q4 2025)

Total Assets $70,830,847,350

Total Liabilities $27,041,242,650

Total Equity $43,715,479,620

Cash & Equivalents $0

Total Debt $2,934,080,000

Current Assets $22,630,490,620

Current Liabilities $23,128,933,780

Long-term Debt $2,934,080,000

Additional Financials

EBITDA -$13,963,234,304

Gross Profit -$6,159,300

Revenue per Share $0.129

Diluted EPS (TTM) $0

EPS Estimates

Current Quarter $0

Current Year $0

Next Quarter $0

Next Year $0

Frequently Asked Questions

Common questions about Bridge Biotherapeutics Inc's Bitcoin holdings

How much Bitcoin does Bridge Biotherapeutics Inc hold?

Bridge Biotherapeutics Inc currently holds 200 BTC, which represents 0.001% of the total Bitcoin supply (21 million). This makes them the 84th largest public Bitcoin holder.

What is the current value of Bridge Biotherapeutics Inc's Bitcoin holdings?

As of today, Bridge Biotherapeutics Inc's Bitcoin holdings are worth approximately $12,337,898. This represents 0.0% of the company's total market value.

What is Bridge Biotherapeutics Inc's average cost basis for Bitcoin?

Bridge Biotherapeutics Inc's average cost basis for their Bitcoin purchases is $26,363,984 per Bitcoin. Their current return on investment (ROI) is -53.20%.

When did Bridge Biotherapeutics Inc last buy Bitcoin?

Bridge Biotherapeutics Inc's most recent Bitcoin purchase was Feb 06, 2026. View purchase details

What type of company is Bridge Biotherapeutics Inc?

Bridge Biotherapeutics Inc is a public company in the Financial Services sector and Capital Markets industry with approximately 21 employees .

What is Bridge Biotherapeutics Inc's market capitalization?

Bridge Biotherapeutics Inc has a market capitalization of approximately $36,442,669,056 and annual revenue of $9,000,000 .

What is Bridge Biotherapeutics Inc's mNAV?

Bridge Biotherapeutics Inc's mNAV (Market-to-Net Asset Value) is 1473.69x, comparing the company's market value to its Bitcoin holdings value. An mNAV of 1.0 means market value equals Bitcoin stash, while >1.0 indicates a premium for the company's Bitcoin strategy.

What is Bridge Biotherapeutics Inc's market cap and enterprise value?

Bridge Biotherapeutics Inc has a market capitalization of $36,442,669,056 and an enterprise value of $39,376,749,056. Enterprise value represents the total company value including debt and cash, providing a more complete valuation picture than market cap alone.